* Ironwood Pharmaceuticals Inc IRWD.OQ reported a
quarterly
adjusted loss of 2 cents per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of 25 cents. The mean expectation of six analysts
for the quarter was for earnings of 19 cents per share. Wall
Street expected results to range from 10 cents to 48 cents per
share.
* Revenue fell 28% to $74.88 million from a year ago;
analysts
expected $105.80 million.
* Ironwood Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 3 cents.
* The company reported a quarterly loss of $4.16 million.
* Ironwood Pharmaceuticals Inc shares had fallen by 6.8%
this
quarter and lost 29.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 25.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $17.50
This summary was machine generated from LSEG data May 9 at 01:52
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 0.19 -0.02 Missed
Dec. 31 2023 0.21 -0.01 Missed
Sep. 30 2023 0.16 0.09 Missed
Jun. 30 2023 0.25 0.31 Beat